Keywords: astrazeneca, iressa, shows, overall, survival, advantage, announced
AstraZeneca's Iressa shows no overall survival advantage
Article | 10 January 2005
AstraZeneca has announced that the initial analysis of the primary endpoint of Study 709, Iressa (gefitinib) Survival Evaluation in Lung cancer ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
